Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MNPR-101-Zr is a zirconium-89 labeled version of MNPR-101, Monopar’s proprietary first-in-class humanized monoclonal antibody that is highly selective against uPAR. It is being developed for the treatment of triple-negative breast, colorectal, & pancreatic cancers.
Lead Product(s): MNPR-101-Zr
Therapeutic Area: Oncology Product Name: MNPR-101-Zr
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Monopar Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024